Company Overview and News

 
Biocon sells 1.88% in research arm for ₹230 cr

2018-05-18 thehindubusinessline
Biotech major Biocon has sold 1.88 per cent stake in its research arm Syngene International for around ₹230 crore. According to a filing in the exchanges, Biocon sold 37,65,574 equity shares amounting to 1.88 per cent of the equity share capital of Syngene through open market sale.

 
Podcast | Sensex cracks 300 points ahead of Karnataka floor test; Nifty below 10,600

2018-05-18 moneycontrol
The S&P BSE Sensex cracked 300 points on Friday amid uncertainty as to who will form the government in Karnataka and rising crude oil prices. The Nifty50 slipped below its crucial support placed at 10,600 which does not augur well for the bulls.

 
Closing Bell: Sensex down 301 pts, Nifty below 10,600; ICICI Bank, LT, Tata Motors dip 3%

2018-05-18 moneycontrol
Market Closing: Benchmark indices ended sharply lower, continuing weakness for the fourth consecutive session amid uncertainty over government formation in Karnataka, likely fiscal imbalance due to higher crude oil prices and weaker rupee.

 
Biocon sells 1.88% stake in Syngene for Rs230 crore

2018-05-18 livemint
New Delhi: Biocon Ltd has sold close to 2% stake in its research arm Syngene International for an estimated Rs230 crore.

 
Market Live: Sensex down over 250 pts; Strides Shasun plunges 25%, Himatsingka up 4%

2018-05-18 moneycontrol
Buzzing: Bhushan Steel share price rallied 5 percent after its board of directors approved allotment of 7.2 crore shares to lenders.

 
Biocon sells 1.9% stake in Syngene

2018-05-18 thehindubusinessline
Biocon Ltd has sold close to 2 per cent stake in its research arm Syngene International for an estimated Rs 230 crore.

 
Syngene International Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Dividend

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Outcome of Board Meeting

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Record Date

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Investor Presentation

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Press Release

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Syngene International Limited - Financial Result Updates

2018-04-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Closing Bell: Nifty ends below 10,600 ahead of FO expiry, Sensex falls 115 pts

2018-04-25 moneycontrol
3:30 pm Market Closing: Benchmark indices closed lower ahead of expiry of April derivative contracts due tomorrow.

 
Market Live: Sensex dips over 150 pts, Nifty breaks 10,550; rupee falls to 66.80/$, Europe down

2018-04-25 moneycontrol
2:40 pm Rupee Update: The Indian rupee extended fall to 66.80 against the US dollar, down 42 paise from previous closing of 66.38 a dollar on bouts of month-end dollar demand from importers amid crude price volatility and rising US bond yields.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...